Hospital
The Health and Hospital Corporation of Marion County
The Health and Hospital Corporation of Marion County was paid $231.53M by Medicaid between Jan 2018 and Dec 2024, across 353 billing codes. Its largest line is A0429, emergency ambulance ride, basic life support — 19% of everything it billed.
33Billing provider infoTHE HEALTH AND HOSPITAL CORPORATION OF MARION COUNTY
INDIANAPOLIS, IN 46202
INDIANAPOLIS, IN 46202
33aNPI1568407310assigned 06/17/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$231.53M
24GClaims3,452,765
24DCodes billed353
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Indiana
Rank by total paid#1 of 5
Median peer was paid$25.59M
This provider vs. median9.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SCOTT, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 504,520 | $14.30M | |
| 2019 | 441,045 | $25.37M | |
| 2020 | 378,948 | $26.57M | |
| 2021 | 499,293 | $35.17M | |
| 2022 | 620,869 | $42.96M | |
| 2023 | 571,778 | $47.44M | |
| 2024incomplete | 436,312 | $39.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 19% | 235,548 | 167,708 | $44.45M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 12% | 128,819 | 107,269 | $28.02M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10.0% | 141,460 | 124,003 | $23.13M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.7% | 85,052 | 75,587 | $13.13M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5.6% | 143,304 | 120,466 | $12.86M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.3% | 78,699 | 66,829 | $12.30M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.9% | 130,639 | 107,539 | $8.95M |
| A0425 | Ground mileage, per statute mile | 3.4% | 379,837 | 270,906 | $7.84M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.8% | 93,547 | 73,211 | $6.39M |
| 71046 | Radiologic examination, chest; 2 views | 2.8% | 51,644 | 43,364 | $6.39M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 2.7% | 4,016 | 3,483 | $6.24M |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 2.4% | 60,589 | 37,646 | $5.57M |
341 more codes
| 90834 | Psychotherapy session, about 45 minutes | 1.8% | 46,407 | $4.07M |
| 99218 | 1.5% | 9,791 | $3.49M | |
| 99285 | Emergency room visit (most serious) | 1.4% | 26,478 | $3.22M |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 25,972 | $2.28M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,660 | $2.13M |
| 94760 | <1% | 30,127 | $2.12M | |
| 94761 | <1% | 29,690 | $1.90M | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 37,623 | $1.73M |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 416 | $1.73M |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 2,308 | $1.71M |
| 90791 | Psychiatric diagnostic evaluation | <1% | 17,179 | $1.55M |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 26,571 | $1.34M |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 11,273 | $1.25M |
| 99221 | <1% | 2,629 | $1.12M | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,955 | $873K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 32,101 | $848K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,889 | $847K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 32,050 | $845K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 11,838 | $796K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 25,058 | $795K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 789 | $785K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 35,154 | $778K |
| 80050 | General health panel | <1% | 5,269 | $745K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 12,804 | $704K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 6,363 | $611K |
| 80053 | Comprehensive metabolic panel | <1% | 89,310 | $610K |
| 85027 | <1% | 144,241 | $603K | |
| 20610 | <1% | 5,590 | $578K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 120,269 | $555K |
| A0433 | Advanced life support, level 2 (als 2) | <1% | 1,571 | $550K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 384 | $528K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,504 | $518K |
| 80061 | Lipid panel | <1% | 51,346 | $508K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 19,445 | $504K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 6,151 | $487K |
| 36415 | Collection of venous blood by venipuncture | <1% | 203,573 | $483K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,702 | $433K |
| 84484 | <1% | 63,992 | $433K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 22,302 | $417K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 7,882 | $408K |
| 31231 | <1% | 788 | $386K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,554 | $373K |
| 71271 | <1% | 1,872 | $363K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 75,980 | $353K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 51,146 | $339K |
| 81025 | <1% | 57,990 | $332K | |
| 20611 | <1% | 1,085 | $329K | |
| 87536 | <1% | 5,961 | $317K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 26,515 | $303K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,791 | $298K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12,422 | $214K |
| 90785 | <1% | 2,627 | $196K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 2,677 | $193K |
| 16020 | <1% | 1,104 | $179K | |
| 43235 | <1% | 158 | $173K | |
| 86780 | <1% | 14,095 | $160K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,579 | $147K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,970 | $146K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 1,481 | $140K |
| 86803 | <1% | 12,668 | $134K | |
| 62323 | <1% | 326 | $134K | |
| 81001 | <1% | 64,680 | $129K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 144 | $123K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,697 | $122K |
| 36416 | <1% | 19,161 | $121K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,103 | $116K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,293 | $114K |
| L4361 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated, off-the-shelf | <1% | 618 | $112K |
| 27447 | <1% | 19 | $111K | |
| E0143 | Walker, folding, wheeled, adjustable or fixed height | <1% | 2,443 | $110K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 562 | $105K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 997 | $105K |
| 90723 | <1% | 1,960 | $101K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 808 | $100K |
| 81002 | <1% | 40,159 | $99K | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 2,106 | $99K |
| 82962 | <1% | 53,684 | $97K | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 94 | $95K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 101 | $94K |
| 83655 | <1% | 7,567 | $93K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,124 | $91K |
| 95886 | <1% | 380 | $89K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,956 | $85K |
| 93923 | <1% | 949 | $82K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,708 | $77K |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 1,581 | $75K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 995 | $67K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 579 | $63K |
| 83690 | <1% | 16,532 | $57K | |
| 87428 | <1% | 1,944 | $57K | |
| J7300 | Intrauterine copper contraceptive (paragard) | <1% | 58 | $54K |
| 95908 | <1% | 470 | $53K | |
| 90651 | <1% | 507 | $52K | |
| L1820 | Knee orthosis, elastic with condylar pads and joints, with or without patellar control, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 702 | $52K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 412 | $50K |
| 96417 | <1% | 481 | $49K | |
| 84403 | <1% | 2,130 | $48K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 847 | $47K |
| 92015 | Determination of refractive state | <1% | 1,134 | $47K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 97 | $46K |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | <1% | 745 | $46K |
| 88142 | <1% | 5,192 | $44K | |
| 92134 | <1% | 2,395 | $44K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 804 | $44K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 589 | $42K |
| 90670 | <1% | 2,700 | $41K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,054 | $41K |
| 86361 | <1% | 2,253 | $38K | |
| 77049 | <1% | 16 | $38K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 462 | $36K |
| L0630 | Lumbar-sacral orthosis, sagittal control, with rigid posterior panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, stays, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 250 | $35K |
| 31575 | <1% | 101 | $33K | |
| 82728 | <1% | 2,789 | $32K | |
| 31579 | <1% | 49 | $30K | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 517 | $29K |
| 83880 | <1% | 1,560 | $29K | |
| G0378 | Hospital observation service, per hour | <1% | 146 | $29K |
| 73564 | <1% | 820 | $28K | |
| 96127 | <1% | 391 | $28K | |
| 36592 | <1% | 1,732 | $28K | |
| 73130 | <1% | 841 | $28K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 148 | $27K |
| 95909 | <1% | 244 | $27K | |
| 96415 | <1% | 264 | $26K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 690 | $26K |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 464 | $25K |
| 73610 | <1% | 618 | $25K | |
| 90838 | <1% | 189 | $25K | |
| 87340 | <1% | 3,961 | $25K | |
| 54161 | <1% | 26 | $25K | |
| 97162 | <1% | 301 | $24K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 996 | $24K |
| 91200 | <1% | 304 | $23K | |
| 54300 | <1% | 15 | $23K | |
| 87522 | Neg quan hep c or qual rna | <1% | 712 | $22K |
| 74018 | <1% | 173 | $22K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 75 | $22K |
| 83718 | <1% | 3,885 | $21K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 37 | $21K |
| 83721 | <1% | 5,012 | $21K | |
| Q3014 | Telehealth originating site facility fee | <1% | 3,088 | $21K |
| 73630 | <1% | 527 | $20K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 46 | $20K |
| 83550 | <1% | 2,868 | $20K | |
| 93017 | <1% | 94 | $20K | |
| 64721 | <1% | 14 | $20K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 236 | $19K |
| 82951 | <1% | 1,726 | $18K | |
| 86762 | <1% | 1,863 | $17K | |
| 83735 | <1% | 4,139 | $16K | |
| 80076 | <1% | 2,736 | $15K | |
| 83540 | <1% | 2,887 | $15K | |
| 82607 | <1% | 1,831 | $15K | |
| 67228 | <1% | 12 | $14K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 779 | $14K |
| V2632 | Posterior chamber intraocular lens | <1% | 148 | $14K |
| 86480 | <1% | 389 | $13K | |
| 82570 | <1% | 4,080 | $13K | |
| 84439 | <1% | 2,717 | $12K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 51 | $12K |
| 82465 | <1% | 3,896 | $12K | |
| 20552 | <1% | 179 | $12K | |
| 71250 | <1% | 90 | $11K | |
| 82043 | <1% | 2,942 | $11K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 725 | $11K |
| 86850 | <1% | 2,863 | $11K | |
| 80348 | <1% | 95 | $9K | |
| 95885 | <1% | 30 | $9K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 17 | $9K |
| 82670 | <1% | 347 | $9K | |
| 59025 | Fetal non-stress test | <1% | 32 | $8K |
| 87631 | <1% | 129 | $8K | |
| 72100 | <1% | 305 | $8K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 622 | $8K |
| 87653 | <1% | 344 | $7K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 925 | $7K |
| E0245 | Tub stool or bench | <1% | 253 | $7K |
| 73560 | <1% | 381 | $7K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 57 | $7K |
| 93926 | <1% | 64 | $7K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 221 | $7K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 473 | $7K |
| 82075 | <1% | 227 | $6K | |
| 86900 | <1% | 2,275 | $6K | |
| 90839 | <1% | 65 | $5K | |
| 90716 | <1% | 88 | $5K | |
| 85660 | <1% | 1,480 | $5K | |
| 96900 | <1% | 60 | $5K | |
| 69210 | <1% | 31 | $5K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 31 | $5K |
| 80069 | <1% | 1,754 | $4K | |
| 86901 | <1% | 2,275 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 111 | $4K |
| 86160 | <1% | 649 | $4K | |
| 77080 | <1% | 107 | $4K | |
| 73030 | <1% | 152 | $4K | |
| 84153 | <1% | 443 | $4K | |
| 51798 | <1% | 234 | $4K | |
| 90620 | <1% | 18 | $4K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 29 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 30 | $4K |
| 85651 | <1% | 1,875 | $4K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 292 | $4K |
| 82150 | <1% | 1,327 | $4K | |
| 84460 | <1% | 1,354 | $3K | |
| 86592 | <1% | 2,297 | $3K | |
| 80325 | <1% | 99 | $3K | |
| 86706 | <1% | 390 | $3K | |
| 87081 | <1% | 462 | $3K | |
| 84450 | <1% | 1,246 | $3K | |
| 93296 | <1% | 13 | $3K | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 428 | $3K |
| 90734 | <1% | 97 | $3K | |
| 81329 | <1% | 95 | $2K | |
| 82565 | <1% | 1,038 | $2K | |
| 36591 | <1% | 17 | $2K | |
| 87902 | <1% | 13 | $2K | |
| 85380 | <1% | 342 | $2K | |
| 52000 | <1% | 17 | $2K | |
| 92555 | <1% | 16 | $2K | |
| 92553 | <1% | 70 | $2K | |
| 86140 | <1% | 580 | $2K | |
| E0100 | Cane, includes canes of all materials, adjustable or fixed, with tip | <1% | 151 | $2K |
| 92557 | <1% | 22 | $2K | |
| 84156 | <1% | 1,004 | $2K | |
| 11056 | <1% | 20 | $2K | |
| 80349 | <1% | 29 | $2K | |
| H2011 | Crisis intervention service, per 15 minutes | <1% | 223 | $2K |
| 87581 | <1% | 95 | $2K | |
| 87486 | <1% | 95 | $2K | |
| 80305 | <1% | 136 | $2K | |
| 85007 | <1% | 472 | $2K | |
| 87660 | <1% | 124 | $1K | |
| 87510 | <1% | 124 | $1K | |
| 87480 | <1% | 124 | $1K | |
| 86704 | <1% | 165 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 95 | $1K |
| 82040 | <1% | 401 | $1K | |
| 73502 | <1% | 42 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 92 | $1K |
| 97760 | <1% | 20 | $976.90 | |
| 86708 | <1% | 102 | $941.36 | |
| 87077 | <1% | 147 | $917.36 | |
| 97163 | <1% | 18 | $916.31 | |
| 83970 | <1% | 65 | $902.59 | |
| 86256 | <1% | 89 | $816.11 | |
| 85610 | <1% | 350 | $712.46 | |
| 84702 | <1% | 59 | $624.25 | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 13 | $598.27 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 392 | $596.56 |
| 76801 | <1% | 15 | $595.36 | |
| 99217 | <1% | 42 | $504.36 | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 595 | $491.74 |
| 96138 | <1% | 13 | $484.59 | |
| 73110 | <1% | 17 | $409.13 | |
| 84100 | <1% | 151 | $402.08 | |
| 51741 | <1% | 14 | $395.82 | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 393 | $386.11 |
| 82950 | <1% | 225 | $360.77 | |
| 82247 | <1% | 72 | $346.38 | |
| 84436 | <1% | 70 | $330.72 | |
| 83605 | <1% | 36 | $311.23 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 8,385 | $298.18 |
| 82274 | <1% | 18 | $273.23 | |
| 82378 | <1% | 16 | $245.91 | |
| 82550 | <1% | 61 | $245.52 | |
| 96152 | <1% | 62 | $244.23 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 35,084 | $225.58 |
| 92133 | <1% | 28 | $220.32 | |
| 87088 | <1% | 29 | $183.89 | |
| 82248 | <1% | 36 | $180.72 | |
| 86703 | <1% | 72 | $180.51 | |
| 90674 | <1% | 1,308 | $156.63 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 24 | $154.86 |
| 96402 | <1% | 21 | $130.47 | |
| J3490 | Unclassified drugs | <1% | 86 | $127.00 |
| 86141 | <1% | 26 | $124.00 | |
| 90653 | <1% | 61 | $123.87 | |
| 80164 | <1% | 16 | $112.42 | |
| 92136 | <1% | 64 | $110.16 | |
| 87186 | <1% | 14 | $109.00 | |
| 80165 | <1% | 14 | $98.88 | |
| 86225 | <1% | 18 | $54.90 | |
| 83037 | <1% | 29 | $46.52 | |
| 82746 | <1% | 12 | $44.10 | |
| G0008 | Administration of influenza virus vaccine | <1% | 227 | $31.05 |
| 85018 | <1% | 15 | $28.44 | |
| 85014 | <1% | 15 | $28.44 | |
| 90661 | <1% | 53 | $21.48 | |
| 90685 | <1% | 512 | $13.62 | |
| Q0112 | All potassium hydroxide (koh) preparations | <1% | 41 | $12.98 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,148 | $9.94 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 39 | $2.72 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 408 | $0.00 |
| A0888 | Noncovered ambulance mileage, per mile (e.g., for miles traveled beyond closest appropriate facility) | 0% | 1,588 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 119 | $0.00 |
| 90686 | 0% | 3,954 | $0.00 | |
| 90474 | 0% | 252 | $0.00 | |
| 90647 | 0% | 2,023 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 111 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 432 | $0.00 |
| 90694 | 0% | 342 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 753 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 44 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 508 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 51 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 143 | $0.00 |
| 97802 | 0% | 137 | $0.00 | |
| 81511 | 0% | 58 | $0.00 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 42 | $0.00 |
| Q0164 | Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 64 | $0.00 |
| 99224 | 0% | 45 | $0.00 | |
| 96139 | 0% | 13 | $0.00 | |
| 99232 | Hospital visit by a doctor, follow-up day | 0% | 20 | $0.00 |
| J2680 | Injection, fluphenazine decanoate, up to 25 mg | 0% | 62 | $0.00 |
| 90696 | 0% | 17 | $0.00 | |
| 90744 | 0% | 14 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 3,347 | $0.00 |
| 90633 | 0% | 961 | $0.00 | |
| 92083 | 0% | 41 | $0.00 | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | 0% | 974 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 168 | $0.00 |
| 90682 | 0% | 149 | $0.00 | |
| G0270 | Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes | 0% | 65 | $0.00 |
| 90681 | 0% | 833 | $0.00 | |
| 90707 | 0% | 118 | $0.00 | |
| 90715 | 0% | 41 | $0.00 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 181 | $0.00 |
| 90700 | 0% | 29 | $0.00 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 104 | $0.00 |
| G0435 | Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening | 0% | 54 | $0.00 |
| 99238 | Hospital discharge day management, 30 minutes or less | 0% | 22 | $0.00 |
| 90710 | 0% | 32 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 15 | $0.00 |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | 0% | 99 | $0.00 |
| 95251 | 0% | 12 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 46 | $0.00 |
| 99401 | 0% | 31 | $0.00 | |
| 81291 | 0% | 43 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 90 | $0.00 |
| 97803 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCOTT, CHRISTOPHER (CHIEF CLINICAL OPERATING OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.